Novo Nordisk sued Eli Lilly on Tuesday, accusing its rival of misleading consumers by claiming Lilly’s drugs work better than Novo’s competing treatments.
The lawsuit, filed in federal court in New Jersey, argues that Lilly’s ads for Zepbound and Mounjaro compared the highest doses of its drugs with lower doses of Novo’s Wegovy and Ozempic. Novo said the ads rely on "outdated" trial data, according to Reuters.
"The ads are maliciously and deceptively false because Lilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk’s medicines," Novo said in its complaint.
Read Full Article Here
